On August 6, Teleflex Incorporated (NYSE:TFX) reported second-quarter results for the period ended June 30, and the numbers told two different stories at once. Revenue from continuing operations climbed to $570.3 million, up 28.9% from a year earlier, while GAAP diluted earnings per share slid to $0.96 from $1.54. Add in a completed divestiture, a fresh share buyback, and a trimmed full-year outlook, and you have a company mid-transformation asking shareholders for patience.
Cash Coming Back To Shareholders
Teleflex’s core businesses did the heavy lifting. Vascular revenue rose 9.0% to $246.3 million, and Surgical grew 9.1% to $112.1 million, both ahead of the roughly 8% and 9% currency-adjusted growth rates reported for those units. Adjusted diluted earnings per share ticked up to $1.76 from $1.73, a smaller gain than the topline growth but a gain nonetheless.
The bigger story is what management did with the balance sheet. Teleflex closed the sale of its OEM business to Montagu and Kohlberg for $1.5 billion in cash, generating an estimated $1.25 billion after tax, and used part of that to pay off its $700 million Term Loan A-2. The company also bought back $250 million of stock in the quarter at an average price of $130.85 per share, leaving $750 million available under its buyback authorization, and it plans another $250 million accelerated repurchase starting August 7, 2026. That capital return is part of why full-year adjusted diluted earnings per share guidance moved up to $6.90 to $7.20.
On the innovation side, Teleflex won FDA approval in late July for EZPLAZ, the first freeze-dried plasma licensed in the United States, and advanced its Freesolve resorbable scaffold program, with four-year data from the BIOMAG-I study showing durable long-term performance, enrollment finished ahead of schedule in BIOMAG-II, and the first patient procedures completed in the U.S. BIOMAG-III trial in June.
Integration Taking Longer Than Planned
That earnings growth looks thinner once you separate the pieces. GAAP diluted earnings per share fell to $0.96 from $1.54 a year earlier. Management also cut its outlook across the board, lowering full-year GAAP revenue growth guidance to a range of 13.40% to 14.40%, GAAP earnings per share guidance to $2.54 to $2.84, and pro forma adjusted constant currency revenue growth guidance to 3.50% to 4.50%.
The reason traces back to the Biotronik Vascular Intervention business Teleflex acquired last year. Integration is progressing, but taking longer than expected, and it shows up in the numbers: Interventional revenue on a pro forma adjusted constant currency basis actually fell 1.0% in the quarter even as reported Interventional revenue jumped 86.1% on the strength of the acquisition itself. Cash on hand also declined, ending the quarter at $316.9 million versus $402.7 million at the end of 2025, and Teleflex added $500 million of new senior notes carrying a 5.875% coupon, well above the 4.625% notes they replaced.
What The Market Is Pricing In
40 funds held Teleflex last quarter, up from 35 the quarter before, which points to institutional buyers adding rather than trimming. Short sellers, though, have not backed off: 17.90% of the float is sold short, a level that signals heavy organized skepticism about where this story goes next. The stock’s forward price-to-earnings ratio sits at 12.39 as of September 4, cheap enough that the market does not appear to be pricing in the raised adjusted earnings guidance. That combination is the tension investors are weighing right now.
Two Different Stocks In One
Teleflex heading into the back half of 2026 looks like two companies stacked on top of each other: one shedding businesses and returning cash to shareholders, the other still digesting a complicated acquisition. The completed OEM sale and the raised adjusted earnings guidance suggest the leaner version of Teleflex is already showing up in the numbers. But the cut to GAAP guidance and the slower-than-expected Vascular Intervention integration argue the transition still has rough edges to smooth out.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Follow Insider Monkey on Google News.
Hedge Fund Resource Center